Fulcrum Therapeutics Inc. (FULC)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Fulcrum Therapeutics NASDAQ: FULC has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.
Fulcrum to merge with Slate in all-stock deal after drug setback
Fulcrum Therapeutics said on Monday it would merge with privately held Slate Medicines in an all-stock deal, as the biotech looks to rebuild its pipeline after it discontinued development of its lead drug candidate last month.
Fulcrum Therapeutics: Buy It For The Strategic Reset
Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to reset. Fulcrum is a financially strong company in operational distress, and it's trading below NCAV, making it comparable to issues that have strongly outperformed the market.
Fulcrum Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 295 | $2,291.63 | $1,056.1 | -$1,235.53 | -53.91% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 40,000 | $146,400 | $155,600 | $9,200 | 6.28% |
| NA Nizar Araji National Bank Of Canada /FI/ | 919 | $2,804.62 | $3,574.91 | $770.29 | 27.47% |
| BG Bart Gancher Intech Investment Management LLC | 16,182 | $70,203.45 | $62,947.98 | -$7,255.47 | -10.33% |
 Point72 Asset Management LP Point72 Asset Management LP | 651,427 | $7.37M | $2.44M | -$4.93M | -66.93% |
Fulcrum Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Edward Tenthoff Piper Sandler | -5,703.1 | $21,956.95 | $22,185.07 | -$228.12 | -1.04% |
Fulcrum Therapeutics Inc. (FULC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fulcrum Therapeutics Inc. ever had a stock split?
Fulcrum Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alexander C. Sapir CEO | NASDAQ (NMS) Exchange | 359616109 CUSIP |
| US Country | 9 Employees | - Last Dividend | - Last Split | 18 Jul 2019 IPO Date |
Overview
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients suffering from genetically defined diseases with a significant unmet medical need. Established in 2015 with its headquarters located in Cambridge, Massachusetts, Fulcrum Therapeutics is at the forefront of developing innovative therapies. The company’s strategic focus lies in addressing rare neuromuscular, muscular, central nervous system, hematologic disorders, cardiomyopathies, and pulmonary diseases. Collaborating with industry leaders such as Acceleron Pharma Inc. and MyoKardia, Inc., Fulcrum is pushing the boundaries in drug discovery and development to modulate specific biological pathways for various targeted indications.
Products and Services
- Losmapimod:
- Pociredir:
- Drug Discovery for Rare Diseases:
A pioneering small molecule in phase III clinical trial specifically designed for the treatment of facioscapulohumeral muscular dystrophy. Losmapimod represents Fulcrum Therapeutics’ commitment to addressing the challenges in neuromuscular diseases by targeting the underlying genetic causes.
Identified as a fetal hemoglobin inducer presently in phase I clinical trial. Pociredir aims to provide a groundbreaking treatment for sickle cell disease and beta-thalassemia. By focusing on these blood disorders, Fulcrum is moving towards fulfilling the urgent need for new, effective treatments for these life-altering conditions.
In addition to its clinical trials for losmapimod and pociredir, Fulcrum Therapeutics is actively engaged in the discovery of drug targets for the treatment of a variety of rare disorders. These include neuromuscular, muscular, central nervous system, and hematologic disorders, along with genetic cardiomyopathies and pulmonary diseases. This effort underscores Fulcrum’s comprehensive approach to tackling complex, rare diseases by exploring and developing new therapeutic pathways.
